Successful treatment of stanozolol induced-hepatotoxicity with silymarin in a bitch

Asian Journal of Animal Sciences

Volumn 5, Issue 3, 2011, Pages 213-218

  Mosallanejad, B ^a   Avizeh, R ^a   Najafzadeh Varzi, H ^a  

^a SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

Author keywords

Hepatotoxicity; Serum enzymes; Silymarin; Stanozolol

Indexed keywords

CANIS FAMILIARIS;

EID: 79957537730     PISSN: 18191878     EISSN: None     Source Type: Journal    
DOI: 10.3923/ajas.2011.213.218     Document Type: Article

References (23)

1. Avizeh, R., H. Najafzadeh, M.R. Razijalali and S. Shirali, 2010. Evaluation of prophylactic and therapeutic effects of silymarin and N-acetylcysteine in acetaminophen-induced hepatotoxicity in cats. J. Vet. Pharmacol. Ther., 33: 95-99.
2. Boothe, D.M., 2001. Small Animal Clinical Pharmacology and Therapeutics. 1st Edn., W.B. Saunders Co, Philadelphia, pp: 444-538.
3. Cowan, L.A, R. McLaughlin, P.W. Toll, S.A. Brown, T.I. Moore, M.D. Butine and G. Milliken, 1977. Effect of stanozolol on body composition, nitrogen balance and food consumption in castrated dogs with chronic renal failure. J. Am. Vet. Med. Assoc, 211: 719-722.
4. Das, S.K. and D.M. Vasudevan, 2006. Protective effects of silymarin, a milk thistle (Silybium marianum) derivative on ethanol-induced oxidative stress in liver. Indian J. Biochem. Biophys, 43: 306-311.
5. Delgado, J, A. Saborido and A. Megias, 2010. Prolonged treatment with the anabolic-androgenic steroid stanozolol increases antioxidant defences in rat skeletal muscle. J. Physiol. Biochem, 66: 63-71.
6. Harkin, K.R, L.A. Cowan, G.A. Andrews, R.J. Basaraba and J.R. Fischer et al., 2000. Hepatotoxicity of stanozolol in cats. J. Am. Vet. Med. Assoc, 217: 681-684.
7. Hsu, W.H, 2008. Handbook of Veterinary Pharmacology. 1st Edn, Wiley-Blackwell, Iowa, USA, pp: 84-112.
8. Kahn, CM. and S. Line, 2007. The Merck/Menal Manual for Pet Health. 1st Edn, Merck and Co, Whitehouse Station, New Jersey, pp: 873-886.
9. Kalender, Y, M. Yel and S. Kalender, 2005. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of Vitamin E and catechin. Toxicol, 209: 39-45.
10. Kayne, S.B. and M.H. Jepson, 2004. Veterinary Pharmacy. 1st Edn, Pharmaceutical Press, UK, pp: 343-423.
11. Lappin, M.R, 2001. Feline Internal Medicine Secrets. 2nd Edn, Hanley Belfus Inc., Philadelphia, pp: 158-161.
12. st Edn, W.B. Saunders Co, USA, pp: 106-339.
13. McConkey, S.E, D.M. Grant and A.E. Cribb, 2009. The role of para-aminophenol in acetaminophen-induced methemoglobinemia in dogs and cats. J. Vet. Pharmacol. Ther, 32: 585-595.
14. Mira, L, M. Silva and C.F. Manso, 1994. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem. Pharmacol, 48: 753-759.
15. Oliveira, C, F.P. Lopasso, F. Laurindo, R.M. Leitao and A.A. Laundanna, 2001. Protection against liver ischemia-reperfusion injury in rats by silymarin or verapamil. Transplant. Proc, 33: 3010-3014.
16. Paulova, J, M. Dvorak, F. Kolouch, L. Vanova and L. Janeckova, 1990. Evaluation of the hepatoprotective and therapeutic effects of silymarin in an experimental carbon tetrachloride intoxication of liver in dogs. Vet. Med, 35: 629-635.
17. Sailer, R, R. Meier and R. Brignoli, 2001. The use of silymarin in the treatment of liver diseases. Drugs, 61:2035-2063.
18. Sumathy, T, S. Subramanian, S. Govindasamy, K. Balakrishna and G. Veluchamy, 2001. Protective role oiBacopa monniera on morphine induced hepatotoxicity in rats. Phytother. Res, 15: 643-645.
19. Tilley, L.P. and F.W.K. Smith, 2005. The 5-Mmute Veterinary Consult. 4th Edn, Lippmcott Williams and Wilkms, Maryland, pp: 1325-1326.
20. Valenzuela, A. and A. Garrido, 1994. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol. Res. (Chile), 27: 105-112.
21. Varzi, H.N., S. Esmailzadeh, H. Morowati, R. Avizeh, A. Shahnan and M.E. Givi, 2007. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J. Vet. Pharmacol. Ther, 30:477-481.
22. Webster, C.R. and J. Cooper, 2009. Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease. Vet. Clin. North Am. Small Anim. Pract., 39: 631-652.
23. Wellington, K. and B. Jarvis, 2001. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs, 15: 465-489.